A comparison of once daily (evening) versus twice daily budesonide therapy from a new multi-dose dry powder inhaler versus twice daily therapy from a conventional dry powder inhaler in children

R. W. Griffioen, For the Airmax Once Daily Investigators Group (Amsterdam, The Netherlands)

Source: Annual Congress 2001 - Updates of asthma therapy in children
Session: Updates of asthma therapy in children
Session type: Thematic Poster Session
Number: 832
Disease area: Airway diseases, Paediatric lung diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
R. W. Griffioen, For the Airmax Once Daily Investigators Group (Amsterdam, The Netherlands). A comparison of once daily (evening) versus twice daily budesonide therapy from a new multi-dose dry powder inhaler versus twice daily therapy from a conventional dry powder inhaler in children. Eur Respir J 2001; 16: Suppl. 31, 832

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Urinary cortisol levels following 400 mcg budesonide twice daily from a novel multi-dose dry powder inhaler compared to a conventional dry powder inhaler in children
Source: Eur Respir J 2001; 18: Suppl. 33, 289s
Year: 2001

Comparison of a formoterol multiple dose dry powder inhaler (MDPI) with a formoterol single dose dry powder inhaler (SDPI) in patients with moderate to severe asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 260s
Year: 2004

A study to evaluate the therapeutic equivalence of a new multidose budesonide dry powder inhaler with a conventional budesonide dry powder inhaler
Source: Eur Respir J 2001; 18: Suppl. 33, 156s
Year: 2001

Efficacy and safety of salbutamol delivered via a novel multidose dry powder inhaler in comparison with two conventional dry powder inhalers and a pMDI in asthmatic subjects
Source: Eur Respir J 2001; 18: Suppl. 33, 50s
Year: 2001

Formoterol: a new pMDI CFC free formulation. Efficacy of the 12µg dosage versus a dry powder inhaler in moderate to severe asthmatic patients
Source: Eur Respir J 2003; 22: Suppl. 45, 284s
Year: 2003

Formoterol: a new pMDI CFC free formulation. cumulative dose safety versus a dry powder
Source: Eur Respir J 2003; 22: Suppl. 45, 473s
Year: 2003

Young children with asthma treated with budesonide inhalation suspension can successfully be transitioned to once-daily budesonide dry powder inhaler
Source: Annual Congress 2007 - Anti-inflammatory therapy for childhood asthma
Year: 2007


Once-daily budesonide: clinical equivalence of two dry powder inhalers (DPIs)
Source: Eur Respir J 2005; 26: Suppl. 49, 339s
Year: 2005

A single blinded randomised trial to compare the efficacy and safety of once daily budesonide (400μg) administered by turbuhaler with beclomethasone dipropionate (400μg) given twice daily through a metered-dose inhaler in patients with mild to
Source: Eur Respir J 2005; 26: Suppl. 49, 503s
Year: 2005

Comparison of two dry powder inhalers containing budesonide in the treatment of asthma in children
Source: Eur Respir J 2002; 20: Suppl. 38, 500s
Year: 2002

Comparison of mometasone furoate dry powder inhaler 400 mcg once daily in the evening with fluticasone propionate metered dose inhaler 250 mcg twice daily in asthma patients previously maintained on fluticasone propionate
Source: Eur Respir J 2003; 22: Suppl. 45, 34s
Year: 2003

Salbutamol delivered via a new multi-dose dry powder inhaler is as safe and efficacious as a pressurised metered dose inhaler in children aged 6-12 years
Source: Eur Respir J 2002; 20: Suppl. 38, 501s
Year: 2002

Formoterol delivered by multi-dose dry powder inhaler (MDDPI) improves nocturnal asthma symptoms
Source: Eur Respir J 2005; 26: Suppl. 49, 50s
Year: 2005

Patients’ ability to use a novel fluticasone propionate/formoterol breath-triggered inhaler (BTI) vs. budesonide/formoterol dry powder inhaler (DPI)
Source: International Congress 2018 – Innovative therapies in asthma and COPD
Year: 2018



A comparison of the efficacy of low dose single inhaler budesonide/formoterol given once and twice daily in patients with mild- to- moderate asthma
Source: Eur Respir J 2007; 30: Suppl. 51, 615s
Year: 2007

Beclometasone/formoterol administered via extrafine dry powder inhaler in controlled asthmatic patients: Comparison with pMDI and beclometasone monotherapy
Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Year: 2012


Comparison of ciclesonide (MDI) once daily and fluticasone propionate (Diskus®) twice daily in the treatment of patients with moderate asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 666s
Year: 2006

In-use in vitro performance of formoterol fumarate dihydrate powder for inhalation (6 and 12 µg/dose) delivered from a novel multidose dry powder inhaler
Source: Eur Respir J 2003; 22: Suppl. 45, 473s
Year: 2003

Scientific rationale for using a single inhaler for asthma control by comparison of the effectiveness and safety of formoterol/budesonide turbuhaler as physician-guided adjustable maintenance dosing regimen versus formoterol/budesonide given as fixed dose of twice daily therapy in the management of bronchial asthma
Source: Annual Congress 2009 - Aspects of clinical asthma
Year: 2009


Long-term preference and ease of use of a novel dry powder inhaler with budesonide in comparison to a conventional inhaler in asthmatic children
Source: Eur Respir J 2001; 18: Suppl. 33, 121s
Year: 2001